


Step Forward
Personalize treatment decisions for RA patients
PrismRA® is a first-of-its kind molecular signature test that gives providers objective insights to drive RA treatment decisions.
The blood test analyzes each patient’s unique molecular signature, predicting if a patient is well suited for TNF inhibitor (TNFi) therapies such as adalimumab, certolizumab pegol, etanercept, golimumab, and infliximab with 90% accuracy.1
Now, providers can help improve their patients’ outcomes by identifying those unlikely to respond adequately to TNFi therapies prior to treatment initiation and directing them to a more appropriate therapy sooner.



Results you can act on
PrismRA predicts a patient’s likelihood of non-response to TNFi therapies.

NO SIGNAL
Molecular signal of non-response not detected

MODERATE
likelihood of non-response

HIGH
likelihood of non-response

VERY HIGH
likelihood of non-response
PrismRA can be easily incorporated into your practice
